In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Sabra Health Care REIT SBRA, and slightly raised its price target from $23.00 to $24.00.
Jefferies noted, “SBRA continues to successfully reduce exposure to both SUNH and the SNF sector through accretive acquisitions. We still see upside via: 1) multiple expansion through further portfolio diversification, and 2) earnings accretion from acquisitions. Raising PT to $24 and maintaining Buy rating.”
Sabra Health Care REIT closed on Tuesday at $21.50.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in